Kazia Therapeutics LTD 6-K Filing
Ticker: KZIA · Form: 6-K · Filed: Mar 30, 2026 · CIK: 0001075880
| Field | Detail |
|---|---|
| Company | Kazia Therapeutics LTD (KZIA) |
| Form Type | 6-K |
| Filed Date | Mar 30, 2026 |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Kazia Therapeutics LTD (ticker: KZIA) to the SEC on Mar 30, 2026.
How long is this filing?
Kazia Therapeutics LTD's 6-K filing is 3 pages with approximately 766 words. Estimated reading time is 3 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 766 words · 3 min read · ~3 pages · Grade level 13.3 · Accepted 2026-03-30 06:08:47
Filing Documents
- ea0283661-6k_kazia.htm (6-K) — 22KB
- ea028366101ex99-1.htm (EX-99.1) — 738KB
- ea028366101_ex99-1img1.jpg (GRAPHIC) — 2KB
- ea028366101_ex99-1img2.jpg (GRAPHIC) — 2KB
- 0001213900-26-035886.txt ( ) — 3727KB
- kzia-20251231.xsd (EX-101.SCH) — 58KB
- kzia-20251231_cal.xml (EX-101.CAL) — 32KB
- kzia-20251231_def.xml (EX-101.DEF) — 149KB
- kzia-20251231_lab.xml (EX-101.LAB) — 310KB
- kzia-20251231_pre.xml (EX-101.PRE) — 170KB
- ea0283661-6k_kazia_htm.xml (XML) — 597KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited. By: /s/ John Friend Name: John Friend Title: Chief Executive Officer Date: March 30, 2026 3